Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy  

作　　者：Matthias Peipp Diana Dudziak Christian Kellner 

机构地区：[1]Division of Antibody-Based Immunotherapy,Department of Medicine I,Christian-Albrechts University and University Hospital Schleswig-Holstein,Kiel,Germany [2]institute of Immunology,Jena University Hospital,Friedrich-Schiller-University,Jena,Germany [3]Comprehensive Cancer Center Central Germany Jena/Leipzig,Jena,Germany [4]Division of Transfusion Medicine,Cell Therapeutics and Haemostaseology,LMU University Hospital,LMU Munich,Munich,Germany

出　　处：《Signal Transduction and Targeted Therapy》2024年第8期3150-3152,共3页信号转导与靶向治疗（英文）

摘　　要：In a recent article published in Science,Sharma et al.describes the essential role of saposins in cross-presentation of tumor membraneassociated antigens by dendritic cells(DC)to CD8^(+)T cells.1 However,antigen cross-presentation,which is fundamental in cancer cell elimination,is hindered in tumor DC by hyperglycosylation of the common saposin precursor prosaposin(pSAP)leading to impaired T cell tumor immunity-yet,the potential of recombinant pSAP to re-establish T cell responses may offer a novel way to counteract immune evasion in a therapeutic approach.

关 键 词：IMPAIRED IMMUNITY 

分 类 号：R730.51[医药卫生—肿瘤]